Levi & Korsinsky notifies investors that it has commenced an investigation into Azenta, Inc. (NASDAQ: AZTA) concerning potential violations of the federal securities laws.
On February 4, 2026, CEO John Marotta told investors Azenta was "entering the year well positioned for continued success" and reaffirmed FY 2026 guidance of 3%-5% organic revenue growth with approximately 300 basis points of adjusted EBITDA margin expansion. On May 5, 2026, the Company reported Q2 FY 2026 results that included a $149 million goodwill impairment charge in its Multiomics segment. The resulting net loss of $160.8 million stood in stark contrast to the growth trajectory management had presented ninety days prior. Alongside the impairment, Azenta reduced its full-year FY 2026 guidance -- trimming the revenue growth and margin expansion targets it had publicly reaffirmed in February. The gap between the Company's stated outlook and its reported results is now the subject of an investigation into potential securities law violations.
If you suffered a loss on your Azenta, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





